RELAPSE PREVENTION AFTER SWITCHING TO RISPERIDONE LONG-ACTING INGECTION- 6 MONTHS MIRROR IMAGE STUDY IN JAPAN
Author(s)
Kuwabara H, Takeda M, Sasatani YJanssen Pharmaceutical KK, Tokyo, Tokyo, Japan
BACKGROUND: Compliance is an important factor for successful clinical management of schizophrenia. Risperidone long-acting injection (RLAI) can improve compliance compared to oral atypical anti-psychotics and several studies found the use of RLAI was associated with reduced hospitalization. RLAI was introduced to Japanese practice from June 2009 and is currently only available atypical anti-psychotic depot medication. OBJECTIVES: To assess the impact of RLAI use on hospitalization as a proxy of relapse in daily practice among Japanese patients with schizophrenia. METHODS: Mirror image comparison of psychiatric related hospitalization was made for 6 months before (pre-RLAI) and 6 months after (post-RLAI) the initiation of RLAI. The data source was commercially available health insurance claims database (Japan Medical Data Center, Tokyo; January, 2009 to June, 2011). The inclusion criteria were patients (20-59 years of age) who were diagnosed with schizophrenia (ICD F20 to F29) and who had continuous enrollment of the Group health insurance for 6 months before and 6 months after the initiation of RLAI. Patients with long-term hospitalization (>6 months) were excluded. Additionally, study patients were restricted to have at least 3 month continuous treatment with RLAI. In the analysis the initiation of RLAI during hospitalization contributed to pre-RLAI hospitalization because previous treatment was considered as failure. RESULTS: A total of 25 patients from 58 patients who were initiated on RLAI met the inclusion criteria. Twenty patients started at outpatient visits and 21 patients continued the RLAI treatment after 6 months. Mean dose was 33.5mg. The proportion of patients requiring psychiatric hospitalization was changed from 28% to 8% between pre- and post-initiating RLAI (P<001). The total number of psychiatric hospitalization was reduced by 82% (11 vs. 2, P=0.02). CONCLUSIONS: Switching from oral anti-psychotics to RLAI may impact on the reduction in hospitalization among Japanese schizophrenic patients. Further investigation is necessary.
Conference/Value in Health Info
2012-09, ISPOR Asia Pacific 2012, Taipei, Taiwan
Value in Health, Vol. 15, No. 7 (November 2012)
Code
PHP45
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Mental Health